Russian Pharmaceutical Technologies (Ruspharmtech, a SKOLKOVO resident) has increased the commercial value of its patent portfolio by obtaining a US patent.
The document includes information on the originality and innovativeness of alofanib, a new product of the company which is the first allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2).
The drug is intended for targeted therapy of oncological diseases. Various research teams have shown that FGFR2 is the target of therapy for such tumors as stomach cancer, lung cancer, ovarian cancer, cholangiocarcinoma, papillary kidney cancer, triple-negative breast cancer, and other. The uniqueness of alofanib described in the patent is in its selective interaction with extracellular part of the receptor like monoclonalantibodies that makes the drug, on the one hand, highly selective and, on the other, devoid of disadvantages of antibodies. The drug has no analogs in the world, which is confirmed by US patent.
Currently, Ruspharmtech completed all preclinical studies and is preparing for clinical phase 1b trials of safety and efficacy of alofanib in patients with gastric cancer.